DrugPatentWatch Database Preview

Endo Pharms Inc Company Profile

« Back to Dashboard

What is the competitive landscape for ENDO PHARMS INC, and what generic alternatives to ENDO PHARMS INC drugs are available?

ENDO PHARMS INC has five approved drugs.

There are fourteen US patents protecting ENDO PHARMS INC drugs.

There are two hundred and thirty-five patent family members on ENDO PHARMS INC drugs in forty-two countries and four supplementary protection certificates in four countries.

Summary for Endo Pharms Inc

International Patents:	235
US Patents:	14
Tradenames:	5
Ingredients:	5
NDAs:	5

Drugs and US Patents for Endo Pharms Inc

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Endo Pharms Inc	MEGACE ES	megestrol acetate	SUSPENSION;ORAL	021778-001	Jul 5, 2005	AB	RX	Yes	Yes	7,101,576
Endo Pharms Inc	VALGANCICLOVIR HYDROCHLORIDE	valganciclovir hydrochloride	TABLET;ORAL	200790-001	Nov 4, 2014	AB	RX	No	No
Endo Pharms Inc	NASCOBAL	cyanocobalamin	SPRAY, METERED;NASAL	021642-001	Jan 31, 2005		RX	Yes	Yes	7,404,489		Y
Endo Pharms Inc	NASCOBAL	cyanocobalamin	SPRAY, METERED;NASAL	021642-001	Jan 31, 2005		RX	Yes	Yes	7,229,636		Y

Expired US Patents for Endo Pharms Inc

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Endo Pharms Inc	MEGACE ES	megestrol acetate	SUSPENSION;ORAL	021778-001	Jul 5, 2005	5,145,684

Paragraph IV (Patent) Challenges for ENDO PHARMS INC drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Injection	250 mg/mL		2014-06-11
	Nasal Spray	500 mcg/spray		2017-04-28

Non-Orange Book US Patents for Endo Pharms Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
6,811,767	Liquid droplet aerosols of nanoparticulate drugs
8,323,641	Nanoparticulate compositions having lysozyme as a surface stabilizer
8,309,136	In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate or nanoparticulate active agent compositions
8,652,464	Method of treatment using nanoparticulate compositions having lysozyme as a surface stabilizer

International Patents for Endo Pharms Inc Drugs

Country	Document Number	Estimated Expiration
Australia	2003301807
European Patent Office	2266542
Japan	2006510726
Mexico	PA04011653

Supplementary Protection Certificates for Endo Pharms Inc Drugs

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
C0003	France		PRODUCT NAME: VALGANCICLOVIR AINSI QUE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET EN PARTICULIER LE CHLORHYDRATE; NAT. REGISTRATION NO/DATE: NL 27380 20021016; FIRST REGISTRATION: NL - RVG 25 992 20010920
C/GB02/027	United Kingdom		PRODUCT NAME: 2-(2-AMINO-1,6-DIHYDRO-6-OXO-PURIN-9-YL)-METHOXY-3-HYDROXY-1-PROPANYL-L-VALINATE HYDROCHLORIDE (VALGANCICLOVIR HYDROCHLORIDE); REGISTERED: NL RVG 25992 20010920; UK PL 00031/0599 20020425
02/028	Ireland		PRODUCT NAME: VALGANCICLOVIR (2-(2-AMINO-1,6-DIHYDRO-6-OXO-PURIN-9-YL)- METHOXY-3-HYDROXY-1-PROPANYL-L-VALINATE) AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; NAT REGISTRATION NO/DATE: 50/150/1 20020913; FIRST REGISTRATION NO/DATE: NL 25992 20010920; PAEDIATRIC INVESTIGATION PLAN: P/0220/2013
00071	Netherlands		PRODUCT NAME: VALGANCICLOVIR, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET HYDROCHLORIDE; REGISTRATION NO/DATE: RVG 25992 20010920

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Endo Pharm
• Endo Pharms
• Endo Pharms Inc
• Endo Ventures Ltd